Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(66.7%)
Early Phase 1
1(16.7%)
Phase 1
1(16.7%)
6Total
N/A(4)
Early Phase 1(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07475858Not ApplicableNot Yet Recruiting

Photobiomodulation, Heart Rate Variability, and Acute Stress

Role: collaborator

NCT05857124Phase 1Completed

A Study Evaluating the Efficacy of the Vielight Neuro RX Gamma in the Treatment of Post COVID-19 Cognitive Impairment

Role: lead

NCT03328195Not ApplicableCompleted

Vielight Neuro RX Gamma - Feasibility Pilot

Role: lead

NCT03484143Not ApplicableSuspended

Neuro RX Gamma - Pivotal Phase

Role: lead

NCT04230577Early Phase 1Unknown

Photobiomodulation to Improve Cognition in TBI, With fMRI

Role: collaborator

NCT04418505Not ApplicableUnknown

Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms

Role: lead

All 6 trials loaded